1327 ET - Johnson & Johnson expects medical technology sales to continue improving in the rest of the year, in part due to strong performance for its cardiovascular segment in its latest quarter, CEO Joaquin Duato says during a call with analysts. Operational sales of the segment were up 22%, driven by particularly strong growth for electrophysiology products and Abiomed, its subsidiary that manufactures cardiovascular medical implant devices, the company says. "Cardiovascular has some of the largest unmet needs in health care, and is one of the fastest-growing spaces in medtech," Duato says.(kelly.cloonan@wsj.com)
(END) Dow Jones Newswires
July 16, 2025 13:27 ET (17:27 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.